
ID: i4fz2c49,
Text: major ongoing clinical trials for covid treatment and studies currently being conducted or scheduled in japan the outbreak of coronavirus disease covid caused by the severe acute respiratory syndrome coronavirus sars cov poses a serious threat to global public health and economies currently hundreds of clinical trials on a wide variety of treatments against covid are being conducted around the world here we conducted a search for ongoing clinical trials for the treatment of covid at the clinicaltrials gov database on april in total clinical trials were identified and of these trials adopted drug intervention and the other trials utilized biological intervention the number of trials stratified by a chief country conducting the investigation were in china in the united states in canada in italy in france and brazil and trials are being performed multinationally the drugs utilized in more than one trials were remdesivir trials lopinavir ritonavir trials hydroxychloroquine trials interferon trials methylprednisolone trials nitric oxide gas trials oseltamivir trials arbidol trials and vitamin c trials we also described the japanese trials which are now being conducted or scheduled utilizing lopinavir ritonavir remdesivir favipiravir ciclesonide and nafamostat

ID: py2ygpzt,
Text: association of the coronavirus disease covid outbreak with enrollment in cancer clinical trials this cohort study investigates how the coronavirus disease covid pandemic is associated with national enrollment in cancer clinical trials

ID: 61ytvjrb,
Text: key points of serious adverse eventand protection of patients in ophthalmic clinical trials during novel coronavirus pneumonia outbreak 中华实验眼科杂志 the prevention and control of novel coronavirus pneumonia is the most priority recently and various measures during the prevention and control period will have varying degrees of impact on the implement of clinical trials however various examinations in ophthalmological clinical trials need close contact between operators and patients which put us at risk of cross infection this paper indicated some suggestions based on the criteria of clinical trials under major public health emergencies the management of clinical trials during epidemic period including the follow up of subjects the treatment of epidemic serious adverse event sae and the management requirements of co sponsors as well as the requirements and management principles for environment subjects examiners and inspection equipment in the process of ophthalmic clinical trials it may be helpful to the ophthalmic clinical trial researchers and subjects during the period of novel coronavirus infection

ID: gey0nidn,
Text: human coronavirus data from four clinical trials of masks and respirators there are few published data on the protection of masks or respirators against coronavirus infections this is an important research question to inform the response to the covid epidemic the transmission modes of human coronaviruses are similar thought to be by droplet contact and sometimes airborne routes there are several randomised clinical trials of masks and respirators but most used clinical endpoints or tested only for influenza in four trials which we conducted we tested for human coronaviruses but only composite viral endpoints were reported in the trials we reviewed and analysed the coronavirus data from four of our trials laboratory confirmed coronavirus infections were identified in our community household trial case health worker trials cases and trial of mask use by sick patients cases no coronavirus infections were transmitted in households to parents who wore p or surgical masks but one child with coronavirus infection transmitted infection to a parent in the control arm no transmissions to close contacts occurred when worn by sick patients with coronavirus infections there was a higher risk of coronavirus infection in hcws who wore a mask compared to a respirator but the difference was not statistically significant these are the only available data on coronavirus infections associated with mask or respirator use more clinical trials are needed to assess the efficacy of respiratory protection against coronavirus infections

ID: vjg2auh7,
Text: human coronavirus data from four clinical trials of masks and respirators there are few published data on the protection of masks or respirators against coronavirus infections this is an important research question to inform the response to the covid epidemic the transmission modes of human coronaviruses are similar thought to be by droplet contact and sometimes airborne routes there are several randomised clinical trials of masks and respirators but most used clinical endpoints or tested only for influenza in four trials which we conducted we tested for human coronaviruses but only composite viral endpoints were reported in the trials we reviewed and analysed the coronavirus data from four of our trials laboratory confirmed coronavirus infections were identified in our community household trial case health worker trials cases and trial of mask use by sick patients cases no coronavirus infections were transmitted in households to parents who wore p or surgical masks but one child with coronavirus infection transmitted infection to a parent in the control arm no transmissions to close contacts occurred when worn by sick patients with coronavirus infections there was a higher risk of coronavirus infection in hcws who wore a mask compared to a respirator but the difference was not statistically significant these are the only available data on coronavirus infections associated with mask or respirator use more clinical trials are needed to assess the efficacy of respiratory protection against coronavirus infections

ID: pazjx1g5,
Text: systematic review of the registered clinical trials for coronavirus disease covid background since the outbreak of coronavirus disease covid many researchers in china have performed related clinical research however systematic reviews of the registered clinical trials are still lacking therefore we conducted a systematic review of clinical trials for covid to summarize their characteristics methods this study is based on the prisma recommendations in the cochrane handbook the chinese clinical registration center and the clinicaltrials gov databases were searched to identify registered clinical trials related to covid the retrieval inception date was february two researchers independently selected the literature based on the inclusion and exclusion criteria extracted data and evaluated the risk of bias results a total of registered clinical trials interventional studies and observational studies for covid were identified the majority of clinical trials were sponsored by chinese hospitals only trials have begun to recruit patients and none of the registered clinical trials have been completed trials were early clinical exploratory trials or in the pre experiment stage trials were phase iii and four trials were phase iv the intervention methods included traditional chinese medicine in trials western medicine in trials and integrated traditional chinese medicine and western medicine in trials the subjects were primarily non critical adult patients years old the median sample size of the trials was iqr and the median length of the trial periods was d iqr d the main outcomes were clinical observation and examinations overall the methodological quality of both the interventional trials and observational studies was low conclusions intensive clinical trials on the treatment of covid using traditional chinese medicine and western medicine are ongoing or will be performed in china however based on the uncertain methodological quality small sample size and long trial duration we will not be able to obtain reliable high quality clinical evidence regarding the treatment of covid in the near future improving the quality of study design prioritizing promising drugs and using different designs and statistical methods are worth advocating and recommending for clinical trials of covid in the future

ID: iwsa760n,
Text: systematic review of the registered clinical trials of coronavirus disease covid background since the outbreak of coronavirus disease covid many researchers in china have immediately carried out clinical research scheme of the covid but there is still a lack of systematic review of registered clinical trials therefore we conducted a systematic review of the clinical trials of covid to summarize the characteristics of the covid registered clinical trials methods this study is based on the recommendations of the prisma in the cochrane handbook the databases from the chinese clinical registration center and the clinicaltrials gov were searched to collect the registered clinical trials of covid the retrieval inception date is february two researchers independently selected the literature based on inclusion and exclusion criteria extracted data and evaluated the risk of bias results a total of registered clinical trials interventional studies and observational studies of covid were obtained a majority of clinical trials were sponsored by chinese hospitals only trials have begun to recruit patients and none of the registered clinical trials had been completed trials were early clinical exploratory trials or in a pre experiment stage trials belonged to phrase ⅲ and trials were phrase ⅳ the methods of intervention included traditional chinese medicine involving trials western medicine involving trials and integrated traditional chinese medicine and western medicine involving trials the subjects were mainly non critical adult patients years old the median sample size of the trials was iqr and the median execute time of the trials was d iqr d the main outcomes were clinical observation and examinations overall both the methodology quality of interventional trials and observational studies were low conclusions disorderly and intensive clinical trials of covid using traditional chinese medicine and western medicine are ongoing or will being carried out in china however based on the low methodology quality and small sample size and long studies execute time we will not be able to obtain reliable high quality clinical evidence about covid treatment in the near future improving the quality of study design prioritizing promising drugs and using different designs and statistical methods are worth advocating and recommending for the clinical trials of covid in china

ID: m23mvaf7,
Text: clinical trials for inflammatory bowel disease a global guidance during covid pandemic the severe acute respiratory syndrome coronavirus sars cov causing coronavirus disease covid pandemic poses major challenges for patients with inflammatory bowel disease to be recruited and maintained in clinical trials however clinical trials offer patients who have failed multiple drugs access to study medications with alternative mode of action and the potential for relief from inflammation mediated symptoms therefore the continuation of clinical trials in ibd during the covid pandemic is important both for participants and the community of ibd patients due to the dire need of an expanded therapeutic armamentarium as the safety of patients in clinical trials is the leading principle we are providing ten specific rules to guide patients and principal investigators safely through the challenging time

ID: 0mn4b0fp,
Text: key points of serious adverse event and protection of patients in ophthalmic clinical trials during novel coronavirus pneumonia outbreak 新型冠状病毒肺炎防控期间眼科临床试验流程管理及受试者随访防护要点 the prevention and control of novel coronavirus pneumonia is the most priority recently and various measures during the prevention and control period will have varying degrees of impact on the implement of clinical trials however various examinations in ophthalmological clinical trials need close contact between operators and patients which put us at risk of cross infection this paper indicated some suggestions based on the criteria of clinical trials under major public health emergencies the management of clinical trials during epidemic period including the follow up of subjects the treatment of epidemic serious adverse event sae and the management requirements of co sponsors as well as the requirements and management principles for environment subjects examiners and inspection equipment in the process of ophthalmic clinical trials it may be helpful to the ophthalmic clinical trial researchers and subjects during the period of novel coronavirus infection

ID: 7izjhyyk,
Text: characteristics of covid clinical trials in china based on the registration data on chictr and clinicaltrials gov objective this study aimed to evaluate the fundamental characteristics of coronavirus disease covid clinical trials registered in china methods covid clinical trials registered in china were analyzed from databases on chictr and clinicaltrials gov the study designs samples primary end points and intervention measures were evaluated results in total intervention clinical trials were retrieved on march overall trials involved two groups trials were randomized parallel trials trials were double blind and of trials included participants sixty trials considered symptom improvement as the primary endpoint and trials considered the rate or time at which the subjects became virus free as the primary endpoint of intervention studies chemical drugs and biological products were studied in intervention studies of which antiviral drugs accounted for and malaria drugs accounted for of the studies among all trials of the studies used traditional chinese medicine tcm used cell therapy and used plasma therapy conclusion this study is the first snapshot of the landscape of covid clinical trials registered in china and provided the basic features of clinical trial designs for the treatment and prevention of covid to offer useful information to guide future clinical trials on covid in other countries

ID: zed7d315,
Text: characteristics of covid clinical trials in china based on the registration data on chictr and clinicaltrials gov objective this study aimed to evaluate the fundamental characteristics of coronavirus disease covid clinical trials registered in china methods covid clinical trials registered in china were analyzed from databases on chictr and clinicaltrials gov the study designs samples primary end points and intervention measures were evaluated results in total intervention clinical trials were retrieved on march overall trials involved two groups trials were randomized parallel trials trials were double blind and of trials included participants sixty trials considered symptom improvement as the primary endpoint and trials considered the rate or time at which the subjects became virus free as the primary endpoint of intervention studies chemical drugs and biological products were studied in intervention studies of which antiviral drugs accounted for and malaria drugs accounted for of the studies among all trials of the studies used traditional chinese medicine tcm used cell therapy and used plasma therapy conclusion this study is the first snapshot of the landscape of covid clinical trials registered in china and provided the basic features of clinical trial designs for the treatment and prevention of covid to offer useful information to guide future clinical trials on covid in other countries

ID: pftu5qea,
Text: clinical trials for the prevention and treatment of covid current state of play since coronavirus disease covid emerged in wuhan china in december and spread around the world over clinical studies have been registered globally on clinical trials registries including over randomised controlled trials such rapid development and launch of clinical trials is impressive but presents challenges including the potential for duplication and competition there is currently no known effective treatment for covid in order to focus on those studies most likely to influence clinical practice we summarise the currently registered randomised trials with a target sample size of at least participants we have grouped these trials into four categories prophylaxis treatment of outpatients with mild covid treatment of hospitalised patients with moderate covid and treatment of hospitalised patients with moderate or severe disease the most common therapeutic agent being trialled currently is hydroxychloroquine trials with potential sample size of over participants followed by lopinavir ritonavir seven trials and remdesevir five trials there are many candidate drugs in pre clinical and early phase development and these form a pipeline for future large clinical trials if current candidate therapies prove ineffective or unsafe

ID: 6wszpqvx,
Text: clinical trials for the prevention and treatment of covid current state of play since coronavirus disease covid emerged in wuhan china in december and spread around the world over clinical studies have been registered globally on clinical trials registries including over randomised controlled trials such rapid development and launch of clinical trials is impressive but presents challenges including the potential for duplication and competition there is currently no known effective treatment for covid in order to focus on those studies most likely to influence clinical practice we summarise the currently registered randomised trials with a target sample size of at least participants we have grouped these trials into four categories prophylaxis treatment of outpatients with mild covid treatment of hospitalised patients with moderate covid and treatment of hospitalised patients with moderate or severe disease the most common therapeutic agent being trialled currently is hydroxychloroquine trials with potential sample size of over participants followed by lopinavir ritonavir seven trials and remdesevir five trials there are many candidate drugs in pre clinical and early phase development and these form a pipeline for future large clinical trials if current candidate therapies prove ineffective or unsafe

ID: di23na30,
Text: review and methodological analysis of trials currently testing treatment and prevention options for the novel coronavirus disease covid globally background as novel coronavirus disease covid cases continue to steeply rise globally within an unprecedented short period of time solid evidence from large randomised controlled trials is still lacking currently numerous trials testing potential treatment and preventative options are undertaken globally objectives we summarised all currently registered clinical trials examining treatment and prevention options for covid pneumonia additionally we evaluated the quality of the retrieved interventional studies data sources the clinicaltrials gov the chinese clinical trial registry and the european union clinical trials register were systematically searched study eligibility criteria registered clinical trials examining treatment and or prevention options for covid were included no language country or study design restrictions were applied withdrawn cancelled studies and trials not reporting therapeutic or preventative strategies for covid were excluded participants and interventions no restrictions in terms of participants age and medical background or type of intervention were enforced methods the registries were searched using the term coronavirus or covid from their inception until th march additional manual search of the registries was also performed eligible studies were summarised and tabulated interventional trials were methodologically analysed excluding expanded access studies and trials testing traditional chinese medicine results in total trials evaluating therapeutic management options studies assessing preventive strategies and studies examining both were retrieved interventional treatment studies were mostly randomised n and open label n with a median number of planned inclusions of iqr major categories of interventions that are currently being investigated are discussed conclusion numerous clinical trials have been registered since the onset of the covid pandemic summarised data on these trials will assist physicians and researchers to promote patient care and guide future research efforts for covid pandemic containment however up to the end of march significant information concerning reported trials was lacking

ID: t1wpujpm,
Text: a brief review of antiviral drugs evaluated in registered clinical trials for covid background although a number of antiviral agents have been evaluated for coronaviruses there are no approved drugs available to provide an overview of the landscape of therapeutic research for covid we conducted a review of registered clinical trials methods a review of currently registered clinical trials was performed on registries including the chinese chictr org cn and us clinicaltrials gov databases to identify relevant studies up to march th the search was conducted using the search terms ncov covid sars cov hcov new coronavirus novel coronavirus we included interventional clinical trials focusing on patients with covid and assessing antiviral drugs or agents findings out of the studies identified clinical trials were selected for data extraction phase iv trials were the most commonly reported study type n however trials did not describe the phase of the study eighty percent n of the trials were randomized with parallel assignment and the median number of planned inclusions was iqr open label studies were the most frequent followed by double blind and single blind studies the most frequently assessed therapies were stem cells therapy n trials lopinavir ritonavir n chloroquine n umifenovir n hydroxychloroquine n plasma treatment n favipiravir n methylprednisolone n and remdesivir n remdesivir was tested in trials with a median of iqr planned inclusions per trial while stem cells therapy was tested in trials but had a median of iqr planned inclusions per trial lopinavir ritonavir was associated with the highest total number of planned inclusions followed by remdesivir only of the clinical trials reported the treatment dose n and only n the duration the primary outcome was clinical in studies virological in radiological in or immunological in three studies interpretation numerous clinical trials have been registered since the beginning of the covid outbreak however a number of information regarding drugs or trial design were lacking funding none

ID: vxqdfiel,
Text: clinical trials on drug repositioning for covid treatment the world health organization who was informed on december about a coronavirus pneumonia outbreak in wuhan hubei province china subsequently on march cases and deaths were reported coronavirus is an enveloped rna virus from the genus betacoronavirus that is distributed in birds humans and other mammals who has named the novel coronavirus disease as covid more than clinical trials have been launched to test coronavirus treatment including some drug repurposing or repositioning for covid hence we performed a search in march of the clinicaltrials gov database the eligibility criteria for the retrieved studies were contain a clinicaltrials gov base identifier number describe the number of participants and the period for the study describe the participants clinical conditions and utilize interventions with medicines already studied or approved for any other disease in patients infected with the novel coronavirus sars cov ncov it is essential to emphasize that this article only captured trials listed in the clinicaltrials gov database we identified clinical trials involving more than medicines such as human immunoglobulin interferons chloroquine hydroxychloroquine arbidol remdesivir favipiravir lopinavir ritonavir oseltamivir methylprednisolone bevacizumab and traditional chinese medicines tcm although drug repurposing has some limitations repositioning clinical trials may represent an attractive strategy because they facilitate the discovery of new classes of medicines they have lower costs and take less time to reach the market and there are existing pharmaceutical supply chains for formulation and distribution

ID: jwrheaph,
Text: clinical trials for coronavirus disease what is being evaluated and what is not since the report of the first case of coronavirus disease covid in china in late december there have been cases worldwide as of march as part of the response to this outbreak there has been an impressive amount of research undertaken to better characterize the disease and to evaluate therapeutic options by march there are more than studies registered in the clinical trials databases addressing covid including more than randomized controlled trials

ID: 6hum16ve,
Text: conducting clinical trials in heart failure during and after the covid pandemic an expert consensus position paper from the heart failure association hfa of the european society of cardiology esc the coronavirus disease covid pandemic caused by the severe acute respiratory syndrome coronavirus sars cov has important implications for the safety of participants in clinical trials and the research staff caring for them and consequently for the trials themselves patients with heart failure may be at greater risk of infection with covid and the consequences might also be more serious but they are also at risk of adverse outcomes if their clinical care is compromised as physicians and clinical trialists it is our responsibility to ensure safe and effective care is delivered to trial participants without affecting the integrity of the trial the social contract with our patients demands no less many regulatory authorities from different world regions have issued guidance statements regarding the conduct of clinical trials during this covid crisis however international trials may benefit from expert guidance from a global panel of experts to supplement local advice and regulations thereby enhancing the safety of participants and the integrity of the trial accordingly the heart failure association of the european society of cardiology on and march conducted web based meetings with expert clinical trialists in europe north america south america australia and asia the main objectives of this expert position paper are to highlight the challenges that this pandemic poses for the conduct of clinical trials in heart failure and to offer advice on how they might be overcome with some practical examples while this panel of experts are focused on heart failure clinical trials these discussions and recommendations may apply to clinical trials in other therapeutic areas

ID: p36zubnf,
Text: vaccines and drug therapeutics to lock down novel coronavirus disease covid a systematic review of clinical trials the ongoing novel coronavirus disease covid pandemic has been responsible for millions of infections and hundreds of thousands of deaths to date there is no approved targeted treatment and many investigational therapeutic agents and vaccine candidates are being considered for the treatment of covid to extract and summarize information on potential vaccines and therapeutic agents against covid at different stages of clinical trials from january to march we reviewed major clinical trial databases such as clinicaltrials gov who international clinical trials registry platform ictrp and other primary registries between january and march interventional studies at different phases under the covid pipeline were included a total of clinical trials were identified between january to march after filtering observational studies studies a total of interventional trials were considered the majority of clinical trials have been conducted on chloroquine n and traditional chinese medications tcms n followed by antivirals n anti inflammatory immunosuppressants n cellular therapies n combinations of different antivirals therapies n antibacterial n and other therapies n five vaccines are under phase i and there are a couple of phase iii trials on the bacillus calmette guérin bcg vaccine under investigation among healthcare workers many novel compounds and vaccines against covid are currently under investigation some candidates have been tested for other viral infections and are listed for clinical trials against the covid pipeline currently there are no effective specific antivirals or drug combinations available for the treatment of covid

ID: 04czoarc,
Text: exclusion of pregnant women from clinical trials during the coronavirus disease pandemic a review of international registries objective pregnant women have been historically excluded from clinical trials for nonobstetric conditions even during prior epidemics the objective of this review is to describe the current state of research for pregnant women during the coronavirus disease covid pandemic study design we conducted a search of international trial registries for trials relating to the novel coronavirus the eligibility criteria for each trial were reviewed for inclusion exclusion of pregnant women relevant data were extracted and descriptive statistics were calculated for individual and combined data the total number of trials from each registry were compared as well as the proportions of pregnancy related trials within each results among trials in the world health organization international clinical trials registry were covid related of those the majority explicitly excluded pregnancy or failed to address pregnancy at all and only were pregnancy specific when categorized by region of covid trials were in asia followed by in europe and in north america of the covid trials which included pregnant women only three were randomized controlled drug trials conclusion approximately of current covid research is pregnancy related and the majority of trials either explicitly exclude or fail to address pregnancy only three interventional trials worldwide involved pregnant women the knowledge gap concerning the safety and efficacy of interventions for covid created by the exclusion of pregnant women may ultimately harm them while ethical concerns about fetal exposure are often cited it is in fact unethical to habitually exclude pregnant women from research key points pregnancy was excluded from past pandemic research pregnancy is being excluded from covid research exclusion of pregnant women is potentially harmful

ID: 68xv786q,
Text: a survey of clinical trials about coronavirus disease in china

ID: ufcvecwo,
Text: outcome reporting from protocols of clinical trials of coronavirus disease covid a review objectives to examine heterogeneity of outcomes in protocols of clinical trials of coronavirus disease covid and to identify outcomes for prioritization in developing a core outcome set cos in this field design this study is a review data sources databases of icmje accepted clinical trial registry platform were searched on february eligibility criteria randomized controlled trials rcts and non rcts of covid were considered conditions of patients include common type severe type or critical type interventions include traditional chinese medicine tcm and western medicine we excluded trials that for discharged patients psychological intervention and complications of covid data extraction and synthesis the general information and outcomes outcome measurement instruments and measurement times were extracted the results were analysed by descriptive analysis results registry platforms were searched a total of protocols were included from protocols for protocols of tcm clinical trials outcomes from outcome domains were reported and almost half of outcomes were reported only once the most frequently reported outcome was time of sars cov rna turns to negative outcomes were provided one or more outcome measurement instruments outcomes were provided one or more measurement time frame for protocols of western medicine clinical trials outcomes from outcome domains were reported almost half of outcomes were reported only once the most frequently reported outcome was proportion of patients with negative sars cov outcomes were provided one or more outcome measurement instruments outcomes were provided one or more measurement time frame conclusion outcome reporting in protocols of clinical trials of covid is inconsistent thus developing a core outcome set is necessary keywords outcomes clinical trials covid review

ID: 8r96391m,
Text: exclusion of pregnant women from clinical trials during the coronavirus disease pandemic a review of international registries objective pregnant women have been historically excluded from clinical trials for nonobstetric conditions even during prior epidemics the objective of this review is to describe the current state of research for pregnant women during the coronavirus disease covid pandemic study design we conducted a search of international trial registries for trials relating to the novel coronavirus the eligibility criteria for each trial were reviewed for inclusion exclusion of pregnant women relevant data were extracted and descriptive statistics were calculated for individual and combined data the total number of trials from each registry were compared as well as the proportions of pregnancy related trials within each results among trials in the world health organization international clinical trials registry were covid related of those the majority explicitly excluded pregnancy or failed to address pregnancy at all and only were pregnancy specific when categorized by region of covid trials were in asia followed by in europe and in north america of the covid trials which included pregnant women only three were randomized controlled drug trials conclusion approximately of current covid research is pregnancy related and the majority of trials either explicitly exclude or fail to address pregnancy only three interventional trials worldwide involved pregnant women the knowledge gap concerning the safety and efficacy of interventions for covid created by the exclusion of pregnant women may ultimately harm them while ethical concerns about fetal exposure are often cited it is in fact unethical to habitually exclude pregnant women from research key points pregnancy was excluded from past pandemic research pregnancy is being excluded from covid research exclusion of pregnant women is potentially harmful

ID: h10o18ss,
Text: more than clinical trials launch to test coronavirus treatments

ID: 3mpymd8a,
Text: emergence of novel coronavirus and progress toward treatment and vaccine in late december a group of patients was observed with pneumonia like symptoms that were linked with a wet market in wuhan china the patients were found to have a novel coronavirus genetically related to a bat coronavirus that was termed sars cov the virus gradually spread worldwide and was declared a pandemic by who scientists have started trials on potential preventive and treatment options currently there is no specific approved treatment for sars cov and various clinical trials are underway to explore better treatments some previously approved antiviral and other drugs have shown some in vitro activity here we summarize the fight against this novel coronavirus with particular focus on the different treatment options and clinical trials exploring treatment as well as work done toward development of vaccines

ID: ykfm38tg,
Text: a comprehensive analysis of clinical trials in the covid pandemic era background and objective despite medical advances we are facing the unprecedented disaster of the coronavirus disease covid pandemic without available treatments and effective vaccines as the covid pandemic has approached its culmination desperate efforts have been made to seek proper treatments and response strategies and the number of clinical trials has been rapidly increasing in this time of the pandemic it is believed that learning lessons from it would be meaningful in preparing for future pandemics thus this study aims at providing a comprehensive landscape of covid related clinical trials based on the clinicaltrials gov database materials and methods up to march we identified a total of eligible clinical trials and reviewed the overview of the studies results until then the most clinical trials were set up in china treatment approaches are the most frequent purpose of the registered studies chloroquine interferon and antiviral agents such as remdesivir lopinavir and ritonavir are agents under investigation in these trials conclusions in this study we introduced the promising therapeutic options that many researchers and clinicians are interested in and to address the hidden issues behind clinical trials in this covid pandemic

ID: dzvfaa8z,
Text: more than clinical trials launch to test coronavirus treatments

ID: iy0h2pyf,
Text: a large number of covid interventional clinical trials were registered soon after the pandemic onset a descriptive analysis abstract background there is a pressing need for evidence based interventions to address the devastating clinical and public health effects of the coronavirus disease covid pandemic the number of registered trials related to covid is increasing by the day objectives to describe the characteristics of the currently registered clinical trials related to covid methods we searched the world health organization who s international clinical trials registry platform ictrp on may we included any entry that is related to covid we abstracted then descriptively analyzed the following characteristics of the registered trials study design status phase primary endpoints experimental interventions and geographic location among other qualifiers results we identified eligible registered trials the majority of trials were initially registered with clinicaltrials gov n and the chinese clinical trial registry chictr n the number of participants to be enrolled across these trials was with a median of participants per trial the most commonly studied intervention category was pharmacologic n with antiparasitic medications being the most common subcategory while over half of trials were already recruiting we identified published peer reviewed results for only of those trials conclusion there is a relatively large number of registered trials but very few results published so far while our findings suggest an appropriate initial response by the research community the real challenge will be to get these trials completed published and translated into practice and policy

ID: zyz2l27h,
Text: inclusion of children in clinical trials of treatments for coronavirus disease covid

ID: d3k26aar,
Text: rapid adaptation of a surgical research unit to conduct clinical trials during the coronavirus pandemic the coronavirus disease covid pandemic has brought most ongoing clinical trials to a standstill while at the same time emphasizing the need for new therapeutic treatments and strategies to mitigate the morbidity and mortality related to covid recent publication of several observational studies has generated much discussion surrounding efficacy of drugs including hydroxychloroquine azithromycin and remdesivir stressing the need for high quality prospective randomized control trials in patients with covid ongoing stay at home orders and institutional policies mandating work from home for non essential employees which includes most research personnel have impacted the ability to implement and conduct clinical studies this article discusses the approach of an experienced clinical trials unit to make adjustments for ongoing studies and ensure the safety of study participants at the same time plans were implemented to continue collection of data to achieve endpoints safely enroll and follow participants in studies offering potential benefit and quickly implement new covid clinical trials the existence of a division of clinical research with regulatory budgeting contracting and coordinating expertise within a department of surgery can successfully accommodate a crisis situation and rapidly adapt to new requirements for the safe efficient and effective conversion to a remote work force without compromising the research process
